Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis
- PMID: 1540262
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis
Abstract
The frequency and distribution of aberrant antigen expression are analyzed on bone marrow aspirates from 80 patients with newly diagnosed acute myeloid leukemia (AML) by multidimensional flow cytometry. Parameters examined are the light scatter profile of the leukemic cells and the correlative expression of different combinations of the CD2, 4, 5, 7, 11b, 11c, 13, 14, 15, 16, 33, 34, 38, and HLA-DR antigens. Antigen expression on leukemic cells in bone marrow is described by characteristic antigen expression patterns describing: (i) the percentage of cells expressing the antigen; (ii) the antigen density; and (iii) the distribution of the antigen on the leukemic cells. Typically the non-myeloid antigens are homogeneously expressed by the leukemic cells, whereas the myeloid associated antigen CD11b, CD11c, CD14, and CD15 are heterogeneously expressed. Comparison of the antigenic profiles of 80 bone marrow aspirates revealed an extreme interclonal heterogeneity. Comparison of the antigen expression patterns found in AML patients with the antigen expression in normal bone marrow revealed four patterns of aberrant antigen expression in AML: (i) expression of nonmyeloid antigens (i.e. CD2, CD5, and CD7 were present in 57, 60, and 37% of the patients, respectively); (ii) asynchronous expression of myeloid associated antigens (i.e. co-expression of CD34 and CD15 in 25% of the patients and expression of CD16 on immature myeloid cells in 15% of the cases); (iii) over-expression of myeloid associated antigens (e.g. CD34 in 16% of the cases and CD14 on neutrophilic cells in 19% of all patients); and (iv) absence of expression of myeloid associated antigens (e.g. lack of CD33 in 21% of the cases and lack of both CD11b and CD15 in 6% of all patients. Multidimensional flow cytometric analysis of bone marrow aspirates of AML patients disclosed that the leukemic cells of each AML patient had a unique antigenic profile and could be discriminated from their normal counterparts based on aberrant antigen expression and typical light scatter profiles. The ability to distinguish leukemic cells from normal cells allows the detection of residual leukemic cells during and after chemotherapy.
Corrected and republished from
- Leukemia 1991 Sep;5(9):757-67
Similar articles
-
[Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi. 2007 Nov;28(11):731-6. Zhonghua Xue Ye Xue Za Zhi. 2007. PMID: 18457262 Chinese.
-
Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.Haematologica. 1993 Nov-Dec;78(6):359-63. Haematologica. 1993. PMID: 7513673
-
The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.Neoplasma. 2005;52(6):517-22. Neoplasma. 2005. PMID: 16284699
-
Immunophenotypic pattern of myeloid populations by flow cytometry analysis.Methods Cell Biol. 2011;103:221-66. doi: 10.1016/B978-0-12-385493-3.00010-3. Methods Cell Biol. 2011. PMID: 21722806 Review.
-
Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping.Leukemia. 1987 Oct;1(10):697-705. Leukemia. 1987. PMID: 3312833 Review.
Cited by
-
Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia.Cancer Manag Res. 2020 Nov 6;12:11411-11419. doi: 10.2147/CMAR.S260825. eCollection 2020. Cancer Manag Res. 2020. PMID: 33192098 Free PMC article.
-
Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.Proteomics. 2017 Mar;17(6):10.1002/pmic.201600361. doi: 10.1002/pmic.201600361. Proteomics. 2017. PMID: 28176486 Free PMC article.
-
Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Bone Marrow Transplant. 2014 Sep;49(9):1129-38. doi: 10.1038/bmt.2014.99. Epub 2014 May 19. Bone Marrow Transplant. 2014. PMID: 24842529 Review.
-
Universal monitoring of minimal residual disease in acute myeloid leukemia.JCI Insight. 2018 May 3;3(9):e98561. doi: 10.1172/jci.insight.98561. JCI Insight. 2018. PMID: 29720577 Free PMC article.
-
Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Int J Hematol. 2013 Jun;97(6):703-16. doi: 10.1007/s12185-013-1365-1. Epub 2013 May 26. Int J Hematol. 2013. PMID: 23709007 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials